Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia

Sponsor
AO Clinical Investigation and Publishing Documentation (Other)
Overall Status
Completed
CT.gov ID
NCT00873548
Collaborator
Synthes Inc. (Industry)
245
1
52
4.7

Study Details

Study Description

Brief Summary

The primary objective of this prospective multicenter study is to assess any fracture fixation complication and revision rates during the clinical use of the Proximal Femoral Nail Antirotation Asia (PFNA Asia) for the treatment of unstable trochanteric fractures.

Condition or Disease Intervention/Treatment Phase
  • Device: PFNA-Asia

Detailed Description

From several studies, e.g. on hip prostheses, it is known that the Asian population has other geometric proportions than Caucasians, e.g. Japanese woman have shorter femoral necks, smaller femoral neck angles and a more anterior bowing of the shaft than white Americans. This was one of the reasons for the development of a new PFNA Asia with adapted sizes and geometry. No controlled clinical data are available whether the rate of mismatch and mismatch-related complications could be reduced.

Study Design

Study Type:
Observational
Actual Enrollment :
245 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation Asia - A Prospective Multicenter Case Series
Study Start Date :
Nov 1, 2007
Actual Primary Completion Date :
Dec 1, 2011
Actual Study Completion Date :
Mar 1, 2012

Arms and Interventions

Arm Intervention/Treatment
PFNA_Asia treated

Device: PFNA-Asia
The operation is performed under regional or general anesthesia and involves the following main steps: Positioning of the patient Definition of the CCD-angle Fracture reduction Determination of the nail diameter Incision Insertion of the device

Outcome Measures

Primary Outcome Measures

  1. Bone/fracture- or implant/surgery-related fracture fixation complication events [6 and 12 weeks, 6 and 12 months]

Secondary Outcome Measures

  1. Mismatch [Perioperatively]

  2. Soft tissue/wound -related or general complications [6 and 12 weeks, 6 and 12 months]

  3. Health-related quality of life assessed by the generic SF-36-instrument and EQ-5D [Baseline, 6 and 12 months]

  4. Walking ability (Parker mobility score) [Baseline, 6 and 12 months]

  5. Range of motion (ROM) [6 and 12 weeks, 6 and 12 months]

  6. Mortality [6 and 12 weeks, 6 and 12 months]

  7. Surgery details and postoperative treatment [till 12 weeks after surgery]

  8. Length of hospital stay [till 12 weeks after surgery]

  9. Capacity to return to pre-residential status [12 weeks]

  10. Bone consolidation and anatomical restoration [6 and 12 weeks, 6 and 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 65 years and older

  • Patients with isolated, unstable, closed trochanteric fractures, classified as AO 31-A2 or AO 31-A3

  • Definitive primary fracture treatment with PFNA Asia within 7 days sustaining the fracture (conversion from an external fixator to the PFNA Asia as an emergency procedure within the first week after the accident is allowed)

  • Signed written informed consent (by the subjects or legal guardian) and agreement to attend the planned follow-ups

  • Willing and able to comply with the post-operative management program

  • Able to understand and read country national language at an elementary level

Exclusion Criteria:
  • Pathologic fracture

  • Patients or legal guardian refusing to sign the informed consent form

  • Patients with previous implants on the fractured hip and femur

  • Drug or alcohol abuse

  • Active malignancy

  • ASA class V and VI

  • Patients who are bed-ridden or wheel-chair ridden prior to injury event

  • Neurological disorders and psychiatric disorders that would preclude reliable assessment (e.g., Parkinson disease, Multiple sclerosis, severe depression)

  • Patients who have participated in any other device or drug related clinical trial within the previous month

Contacts and Locations

Locations

Site City State Country Postal Code
1 Toyama Municipal Hospital Toyama Japan 939-8511

Sponsors and Collaborators

  • AO Clinical Investigation and Publishing Documentation
  • Synthes Inc.

Investigators

  • Principal Investigator: Takeshi Sawaguchi, MD, Toyama Municipal Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
AO Clinical Investigation and Publishing Documentation
ClinicalTrials.gov Identifier:
NCT00873548
Other Study ID Numbers:
  • PFNA_Asia
First Posted:
Apr 1, 2009
Last Update Posted:
Jul 22, 2021
Last Verified:
Jan 1, 2013
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 22, 2021